Tilray to Close Canadian Cannabis Facility, Targets $10 Million in Annual Savings

By Nicolás Rodríguez, Managing Editor

Tilray Brands is consolidating its Canadian cannabis production, closing its Foss facility in Fenwick, Ontario, and transferring operations to other sites in a restructuring expected to generate approximately $10 million in annualized savings.

The company announced November 2 that cultivation currently handled at Foss will move to its Masson facility in Quebec, while pre-roll production will shift to Cayuga, Ontario.

The transition is expected to be completed by January 31, 2027, following the facility’s remaining cultivation and harvest cycles. Tilray expects to achieve the full annualized savings run rate beginning in fiscal 2028.

The announcement also included an increase to the lower end of Tilray’s fiscal 2027 adjusted EBITDA guidance, from $68 million to $70 million. The upper end remains unchanged at $75 million.

Higher Yields, Fewer Facilities

Tilray’s restructuring reflects a shift toward concentrating production in facilities that can deliver greater output at lower operating costs.

The company said higher-than-expected yields at Masson will allow it to increase the facility’s annual cultivation capacity from approximately 32.5 metric tonnes to 50 metric tonnes.

That additional capacity will absorb cultivation currently conducted at Foss while providing room for additional strains and product development.

The decision also affects Tilray’s Redecan brand, whose products will continue to be supplied during the transition.

“The size of the Foss facility limited the number of strains we could efficiently manage,” said Blair MacNeil, president of Tilray Canada.

Tilray said affected employees have been offered opportunities at other company facilities.

Pre-Rolls Remain an Important Business

The company will move pre-roll manufacturing to Cayuga, where it expects to improve production efficiency and make greater use of existing infrastructure.

Pre-rolls account for approximately one-third of Tilray’s Canadian adult-use cannabis sales and recorded 28% growth in fiscal 2026.

Concentrating production could help reduce redundant operating expenses while supporting a product category that continues to contribute significantly to the company’s Canadian business.

International Expansion Remains Part of the Strategy

Tilray also expects Masson to regain its previous EU-GMP certification during calendar 2027, potentially expanding the facility’s ability to serve regulated international medical cannabis markets.

The company expects to ship more than eight metric tonnes of cannabis to international markets during the current fiscal year.

Tilray’s Canadian cultivation platform spans approximately 4.2 million square feet, including facilities in Ontario, Quebec and British Columbia.

The restructuring therefore represents a reallocation of production across an existing network rather than a withdrawal from Canadian cannabis cultivation.

Cost Reductions and the Profitability Challenge

The consolidation comes while Tilray faces pressure on cannabis sales, making the relationship between operating efficiency and revenue growth particularly important.

Moving production to higher-yield facilities can reduce costs per unit, eliminate redundant expenses, and improve capacity utilization.

However, the anticipated $10 million in annualized savings remains a projection, and the company will need to execute the transition without disrupting supply or compromising product quality.

Tilray’s revised adjusted EBITDA guidance also does not represent an equivalent increase in expected net income or operating cash flow.

The restructuring illustrates a broader challenge facing established Canadian cannabis producers: maintaining sufficient production capacity while reducing the cost of operating infrastructure built for a highly competitive market.

Tilray expects its consolidated operations to support domestic demand, international medical cannabis exports, and potential future U.S. medical cannabis opportunities where permitted. These issues will be central to discussions at the IgniteIt Cannabis Capital & Policy Summit in Washington, D.C., on November 18, where industry executives, investors, and policymakers will examine the future of U.S. cannabis markets.